A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

Administered By

Awarded By

Contributors

Start/End

  • June 25, 2019 - August 31, 2024